[{"id":"056fe673-cdf1-43ac-850b-4889f543f569","acronym":"","url":"https://clinicaltrials.gov/study/NCT03169790","created_at":"2021-01-18T15:37:43.674Z","updated_at":"2025-02-25T12:26:42.620Z","phase":"Phase 1/2","brief_title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","source_id_and_acronym":"NCT03169790","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 12/23/2021","study_completion_date":" 12/23/2021","last_update_posted":"2025-02-24"},{"id":"21aa57fd-3489-4d2b-b37d-e3d304aa4f47","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616209","created_at":"2021-01-19T20:33:34.222Z","updated_at":"2025-02-25T14:40:41.368Z","phase":"Phase 1/2","brief_title":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT04616209","lead_sponsor":"Precision Biotech Taiwan Corp.","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PB103"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/15/2020","start_date":" 11/15/2020","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-14"},{"id":"74bef0ec-e64e-4efc-a1bb-a54c18f7a818","acronym":"","url":"https://clinicaltrials.gov/study/NCT04220684","created_at":"2021-01-18T20:32:37.858Z","updated_at":"2025-02-25T16:32:03.029Z","phase":"Phase 1","brief_title":"Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML","source_id_and_acronym":"NCT04220684","lead_sponsor":"Sumithira Vasu","biomarkers":" IL21","pipe":"","alterations":" ","tags":["IL21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • decitabine • fludarabine IV • SAR445419"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 10/22/2024","primary_completion_date":" 10/22/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"92c099b7-baf6-420f-bbb6-7c2961993e03","acronym":"","url":"https://clinicaltrials.gov/study/NCT05674526","created_at":"2023-01-06T15:58:52.282Z","updated_at":"2025-02-25T16:39:35.039Z","phase":"Phase 1","brief_title":"A Phase 1b Study of WU-NK-101 in Combination With Cetuximab","source_id_and_acronym":"NCT05674526","lead_sponsor":"Wugen, Inc.","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • EGFR expression • RAS mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • EGFR expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • WU-NK-101"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-07"},{"id":"859a89b8-6d9a-45a8-8b58-c39505541de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06693973","created_at":"2025-02-26T10:02:11.282Z","updated_at":"2025-02-26T10:02:11.282Z","phase":"Phase 1","brief_title":"An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT06693973","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 12/27/2023","start_date":" 12/27/2023","primary_txt":" Primary completion: 01/13/2026","primary_completion_date":" 01/13/2026","study_txt":" Completion: 01/13/2026","study_completion_date":" 01/13/2026","last_update_posted":"2024-11-19"},{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"9a54d64d-2889-431d-bba8-38823f83de86","acronym":"","url":"https://clinicaltrials.gov/study/NCT05922930","created_at":"2023-06-28T14:08:31.873Z","updated_at":"2024-07-02T16:34:25.851Z","phase":"Phase 1/2","brief_title":"Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer","source_id_and_acronym":"NCT05922930","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • TACSTD2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • TROP2 expression","tags":["BRCA1 • BRCA2 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-06-14"},{"id":"89a914ac-06d5-4cf1-bba9-6ccd8e3df332","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083883","created_at":"2023-10-16T16:13:47.307Z","updated_at":"2024-07-02T16:34:59.004Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1","source_id_and_acronym":"NCT06083883","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B • SSX1","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • CTAG1B • SSX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/27/2024","start_date":" 03/27/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2024-06-04"},{"id":"8af52e0c-a6ec-4403-a6fa-b9543bc969cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066359","created_at":"2023-10-04T15:10:43.929Z","updated_at":"2024-07-02T16:34:59.118Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06066359","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-06-04"},{"id":"d849c811-e1a4-4e2a-879f-f191f73d4644","acronym":"TCD17197","url":"https://clinicaltrials.gov/study/NCT05086315","created_at":"2023-08-14T10:11:07.011Z","updated_at":"2024-07-02T16:35:00.248Z","phase":"Phase 1/2","brief_title":"First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT05086315 - TCD17197","lead_sponsor":"Sanofi","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bexatamig (IPH6101)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/11/2025","primary_completion_date":" 12/11/2025","study_txt":" Completion: 11/11/2026","study_completion_date":" 11/11/2026","last_update_posted":"2024-05-29"},{"id":"531ae39e-01c4-436e-9a46-eb2502847532","acronym":"LuminICE-203","url":"https://clinicaltrials.gov/study/NCT05883449","created_at":"2023-06-01T14:07:49.446Z","updated_at":"2024-07-02T16:35:00.909Z","phase":"Phase 2","brief_title":"Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL","source_id_and_acronym":"NCT05883449 - LuminICE-203","lead_sponsor":"Affimed GmbH","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-27"},{"id":"84516b21-8265-457c-a480-fa67aca332aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04837196","created_at":"2021-04-08T12:52:25.748Z","updated_at":"2024-07-02T16:35:01.857Z","phase":"Phase 1/2","brief_title":"Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen","source_id_and_acronym":"NCT04837196","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • BRAF • ALK • WT1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • BRAF • ALK • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP7517"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-23"},{"id":"fe141ae7-4238-43b1-a6a8-019252bc4d9e","acronym":"KEYNOTE F92","url":"https://clinicaltrials.gov/study/NCT05597839","created_at":"2022-10-28T13:56:59.300Z","updated_at":"2025-02-25T16:18:16.558Z","phase":"Phase 1/2","brief_title":"Study of DF9001 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05597839 - KEYNOTE F92","lead_sponsor":"Dragonfly Therapeutics","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" RET mutation • RAS wild-type","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • DF9001"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-05-15"},{"id":"a339dfb3-6028-4f3a-ac08-8ffbfee76968","acronym":"","url":"https://clinicaltrials.gov/study/NCT05703854","created_at":"2023-01-30T18:59:49.752Z","updated_at":"2024-07-02T16:35:07.538Z","phase":"Phase 1/2","brief_title":"Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma","source_id_and_acronym":"NCT05703854","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-04-25"},{"id":"93d8c998-c05e-429c-9692-227cbaba07cb","acronym":"NK4AML","url":"https://clinicaltrials.gov/study/NCT04347616","created_at":"2021-01-18T21:02:03.736Z","updated_at":"2024-07-02T16:35:08.070Z","phase":"Phase 1/2","brief_title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","source_id_and_acronym":"NCT04347616 - NK4AML","lead_sponsor":"Radboud University Medical Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • oNKord (inaleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-04-23"},{"id":"8deded4a-9926-4f1a-a26a-90e378ae94dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577755","created_at":"2023-11-14T19:14:53.297Z","updated_at":"2024-07-02T16:35:08.364Z","phase":"Phase 2","brief_title":"Pomalidomide Treatment in Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT04577755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/18/2022","start_date":" 03/18/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-22"},{"id":"fbe8186c-c60a-4c49-92e0-965cd737994f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04473911","created_at":"2022-01-21T22:06:37.324Z","updated_at":"2024-07-02T16:35:16.007Z","phase":"Phase 1","brief_title":"Haplo Peripheral Blood Sct In GVHD Prevention","source_id_and_acronym":"NCT04473911","lead_sponsor":"Zachariah Michael DeFilipp","biomarkers":" HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/14/2020","start_date":" 08/14/2020","primary_txt":" Primary completion: 10/22/2023","primary_completion_date":" 10/22/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-07"},{"id":"323ff3de-ebe5-4dfb-87f7-504068340771","acronym":"","url":"https://clinicaltrials.gov/study/NCT06138587","created_at":"2023-11-18T22:15:34.208Z","updated_at":"2024-07-02T16:35:17.114Z","phase":"Phase 1","brief_title":"Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT06138587","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • CIML NK"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/24/2024","start_date":" 01/24/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-02-28"},{"id":"3914247b-96ea-451f-8ee1-b8dc8967ecc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066424","created_at":"2023-10-04T15:10:44.941Z","updated_at":"2024-07-02T16:35:18.780Z","phase":"Phase 1","brief_title":"Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)","source_id_and_acronym":"NCT06066424","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2 • PD-L1 • BRAF • ALK • ROS1 • NTRK • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression","tags":["EGFR • HER-2 • PD-L1 • BRAF • ALK • ROS1 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/24/2023","start_date":" 10/24/2023","primary_txt":" Primary completion: 04/30/2038","primary_completion_date":" 04/30/2038","study_txt":" Completion: 04/30/2040","study_completion_date":" 04/30/2040","last_update_posted":"2024-02-19"},{"id":"71fc721d-5bad-462d-8429-6b4666cc5367","acronym":"","url":"https://clinicaltrials.gov/study/NCT04024761","created_at":"2021-01-18T19:45:31.523Z","updated_at":"2024-07-02T16:35:20.644Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04024761","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CIML NK • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2019","start_date":" 08/31/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-06"},{"id":"ce910ebc-2111-40c9-8011-63c73b539176","acronym":"","url":"https://clinicaltrials.gov/study/NCT04898543","created_at":"2021-05-24T15:53:54.007Z","updated_at":"2024-07-02T16:35:22.660Z","phase":"Phase 1","brief_title":"QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04898543","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD4 • NKG2D","pipe":"","alterations":" ","tags":["CD4 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/21/2021","start_date":" 06/21/2021","primary_txt":" Primary completion: 06/21/2024","primary_completion_date":" 06/21/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-23"},{"id":"8faf38c0-263f-4288-a94e-9012fdb460fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01697527","created_at":"2021-03-25T16:35:32.028Z","updated_at":"2024-07-02T16:35:26.667Z","phase":"Phase 2","brief_title":"Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies","source_id_and_acronym":"NCT01697527","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 11/02/2012","start_date":" 11/02/2012","primary_txt":" Primary completion: 11/02/2024","primary_completion_date":" 11/02/2024","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2023-12-11"},{"id":"5d643950-2bd3-459b-9947-9ffdee8a0b7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06097962","created_at":"2023-10-24T15:13:56.310Z","updated_at":"2024-07-02T16:35:31.830Z","phase":"Phase 1","brief_title":"Safety and Efficacy of NK510 to Treat NSCLC","source_id_and_acronym":"NCT06097962","lead_sponsor":"Base Therapeutics (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Tevimbra (tislelizumab-jsgr) • Cejemly (sugemalimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-25"},{"id":"e0b289b2-400b-4353-a2bf-4b76dfb7f062","acronym":"","url":"https://clinicaltrials.gov/study/NCT06098898","created_at":"2023-10-25T19:13:53.207Z","updated_at":"2024-07-02T16:35:31.813Z","phase":"Phase 1","brief_title":"Safety and Efficacy of NK510 to Treat Gastric Cancer","source_id_and_acronym":"NCT06098898","lead_sponsor":"Base Therapeutics (Shanghai) Co., Ltd.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 expression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 9","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-10-25"}]